Literature DB >> 14645143

Anandamide initiates Ca(2+) signaling via CB2 receptor linked to phospholipase C in calf pulmonary endothelial cells.

Cristina Zoratti1, Dijle Kipmen-Korgun, Karin Osibow, Roland Malli, Wolfgang F Graier.   

Abstract

The endocannabinoid anandamide has been reported to affect neuronal cells, immune cells and smooth muscle cells via either CB1 or CB2 receptors. In endothelial cells, the receptors involved in activating signal transduction are still unclear, despite the fact that anandamide is produced in this cell type. The present study was designed to explore in detail the effect of this endocannabinoid on Ca2+ signaling in single cells of a calf pulmonary endothelial cell line. Anandamide initiated a transient Ca2+ elevation that was prevented by the CB2 receptor antagonist SR144528, but not by the CB1 antagonist SR141716A. These data were confirmed by molecular identification of the bovine CB2 receptor in these endothelial cells by partial sequencing. The phospholipase C inhibitor 1-[6-[[(17beta)-3-methoxyestra-1,3,5(10)-trien-17-yl]amino]hexyl]-1H-pyrrole-2,5dione and the inositol 1,4,5-trisphosphate receptor antagonist 2-aminoethoxydiphenylborate prevented Ca2+ signaling in response to anandamide. Using an improved cameleon probe targeted to the endoplasmic reticulum (ER), fura-2 and ratiometric-pericam, which is targeted to the mitochondria, anandamide was found to induce Ca2+ depletion of the ER accompanied by the activation of capacitative Ca2+ entry (CCE) and a transient elevation of mitochondrial Ca2+. These data demonstrate that anandamide stimulates the endothelial cells used in this study via CB2 receptor-mediated activation of phospholipase C, formation of inositol 1,4,5-trisphosphate, Ca2+ release from the ER and subsequent activation of CCE. Moreover, the cytosolic Ca2+ elevation was accompanied by a transient Ca2+ increase in the mitochondria. Thus, in addition to its actions on smooth muscle cells, anandamide also acts as a powerful stimulus for endothelial cells.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14645143      PMCID: PMC1574152          DOI: 10.1038/sj.bjp.0705529

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  56 in total

1.  Fluorescent indicators for Ca2+ based on green fluorescent proteins and calmodulin.

Authors:  A Miyawaki; J Llopis; R Heim; J M McCaffery; J A Adams; M Ikura; R Y Tsien
Journal:  Nature       Date:  1997-08-28       Impact factor: 49.962

2.  (R)-methanandamide inhibits receptor-induced calcium responses by depleting internal calcium stores in cultured astrocytes.

Authors:  L Venance; S Sagan; C Giaume
Journal:  Pflugers Arch       Date:  1997-05       Impact factor: 3.657

3.  Production and physiological actions of anandamide in the vasculature of the rat kidney.

Authors:  D G Deutsch; M S Goligorsky; P C Schmid; R J Krebsbach; H H Schmid; S K Das; S K Dey; G Arreaza; C Thorup; G Stefano; L C Moore
Journal:  J Clin Invest       Date:  1997-09-15       Impact factor: 14.808

4.  SR141716A, a potent and selective antagonist of the brain cannabinoid receptor.

Authors:  M Rinaldi-Carmona; F Barth; M Héaulme; D Shire; B Calandra; C Congy; S Martinez; J Maruani; G Néliat; D Caput
Journal:  FEBS Lett       Date:  1994-08-22       Impact factor: 4.124

5.  Involvement of a cannabinoid in endothelium-derived hyperpolarizing factor-mediated coronary vasorelaxation.

Authors:  M D Randall; D A Kendall
Journal:  Eur J Pharmacol       Date:  1997-09-24       Impact factor: 4.432

6.  Evidence that anandamide and EDHF act via different mechanisms in rat isolated mesenteric arteries.

Authors:  F Plane; M Holland; G J Waldron; C J Garland; J P Boyle
Journal:  Br J Pharmacol       Date:  1997-08       Impact factor: 8.739

7.  Activation of peripheral CB1 cannabinoid receptors in haemorrhagic shock.

Authors:  J A Wagner; K Varga; E F Ellis; B A Rzigalinski; B R Martin; G Kunos
Journal:  Nature       Date:  1997-12-04       Impact factor: 49.962

8.  An endogenous cannabinoid as an endothelium-derived vasorelaxant.

Authors:  M D Randall; S P Alexander; T Bennett; E A Boyd; J R Fry; S M Gardiner; P A Kemp; A I McCulloch; D A Kendall
Journal:  Biochem Biophys Res Commun       Date:  1996-12-04       Impact factor: 3.575

9.  Molecular characterization of a peripheral receptor for cannabinoids.

Authors:  S Munro; K L Thomas; M Abu-Shaar
Journal:  Nature       Date:  1993-09-02       Impact factor: 49.962

10.  Bradykinin- and thrombin-induced increases in endothelial permeability occur independently of phospholipase C but require protein kinase C activation.

Authors:  J L Aschner; H Lum; P W Fletcher; A B Malik
Journal:  J Cell Physiol       Date:  1997-12       Impact factor: 6.384

View more
  46 in total

Review 1.  CB2: a cannabinoid receptor with an identity crisis.

Authors:  Brady K Atwood; Ken Mackie
Journal:  Br J Pharmacol       Date:  2010-06       Impact factor: 8.739

2.  Anandamide reduces infarct size in rat isolated hearts subjected to ischaemia-reperfusion by a novel cannabinoid mechanism.

Authors:  Nichola J Underdown; C Robin Hiley; William R Ford
Journal:  Br J Pharmacol       Date:  2005-11       Impact factor: 8.739

Review 3.  Endocannabinoids and cannabinoid receptors in ischaemia-reperfusion injury and preconditioning.

Authors:  P Pacher; G Haskó
Journal:  Br J Pharmacol       Date:  2007-11-19       Impact factor: 8.739

4.  Cannabinoid-2 receptor agonist HU-308 protects against hepatic ischemia/reperfusion injury by attenuating oxidative stress, inflammatory response, and apoptosis.

Authors:  Mohanraj Rajesh; Hao Pan; Partha Mukhopadhyay; Sándor Bátkai; Douglas Osei-Hyiaman; György Haskó; Lucas Liaudet; Bin Gao; Pál Pacher
Journal:  J Leukoc Biol       Date:  2007-07-25       Impact factor: 4.962

5.  CB2-receptor stimulation attenuates TNF-alpha-induced human endothelial cell activation, transendothelial migration of monocytes, and monocyte-endothelial adhesion.

Authors:  Mohanraj Rajesh; Partha Mukhopadhyay; Sándor Bátkai; György Haskó; Lucas Liaudet; John W Huffman; Anna Csiszar; Zoltan Ungvari; Ken Mackie; Subroto Chatterjee; Pál Pacher
Journal:  Am J Physiol Heart Circ Physiol       Date:  2007-07-27       Impact factor: 4.733

Review 6.  Emerging role of the cannabinoid receptor CB2 in immune regulation: therapeutic prospects for neuroinflammation.

Authors:  Guy A Cabral; LaToya Griffin-Thomas
Journal:  Expert Rev Mol Med       Date:  2009-01-20       Impact factor: 5.600

Review 7.  Cannabinoids as therapeutic agents for ablating neuroinflammatory disease.

Authors:  G A Cabral; L Griffin-Thomas
Journal:  Endocr Metab Immune Disord Drug Targets       Date:  2008-09       Impact factor: 2.895

8.  CB2 cannabinoid receptor agonists attenuate TNF-alpha-induced human vascular smooth muscle cell proliferation and migration.

Authors:  M Rajesh; P Mukhopadhyay; G Haskó; J W Huffman; K Mackie; P Pacher
Journal:  Br J Pharmacol       Date:  2007-11-12       Impact factor: 8.739

9.  Cannabinoids as anticancer therapeutic agents.

Authors:  Olga Kovalchuk; Igor Kovalchuk
Journal:  Cell Cycle       Date:  2020-04-05       Impact factor: 4.534

10.  Update on vascular endothelial Ca(2+) signalling: A tale of ion channels, pumps and transporters.

Authors:  Francesco Moccia; Roberto Berra-Romani; Franco Tanzi
Journal:  World J Biol Chem       Date:  2012-07-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.